Provided by Tiger Trade Technology Pte. Ltd.

Molecular Partners AG

4.70
+0.09001.95%
Post-market: 4.700.00000.00%16:04 EST
Volume:2.11K
Turnover:9.88K
Market Cap:175.78M
PE:-2.31
High:4.73
Open:4.61
Low:4.54
Close:4.61
52wk High:5.10
52wk Low:3.36
Shares:37.40M
Float Shares:14.89M
Volume Ratio:0.29
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0363
EPS(LYR):-1.7524
ROE:-51.41%
ROA:-27.01%
PB:1.43
PE(LYR):-2.68

Loading ...

Analysts Offer Insights on Healthcare Companies: Molecular Partners (MOLN) and SI-Bone (SIBN)

TIPRANKS
·
Feb 03

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

GlobeNewswire
·
Feb 02

HC Wainwright Initiates Molecular Partners AG at Buy

MT Newswires Live
·
Jan 27

Molecular Partners Ag : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $13

THOMSON REUTERS
·
Jan 27

Molecular Partners initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Jan 27

Molecular Partners (MOLN) Gets a Buy from LifeSci Capital

TIPRANKS
·
Jan 20

Molecular Partners provided update on latest progress, 2026 milestones

TIPRANKS
·
Jan 12

Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
Jan 12

Press Release: Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics

Dow Jones
·
Dec 11, 2025

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting

GlobeNewswire
·
Dec 07, 2025

Molecular Partners presents new MP0712 data

TIPRANKS
·
Nov 12, 2025

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

GlobeNewswire
·
Nov 12, 2025

Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting

GlobeNewswire
·
Nov 03, 2025

Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

GlobeNewswire
·
Nov 03, 2025

Molecular Partners Q3 EPS $(1.65) Misses $(0.46) Estimate

Benzinga
·
Oct 31, 2025

Press Release: Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

Dow Jones
·
Oct 31, 2025

Molecular Partners Q2 EPS $(0.67) Down from $(0.56) YoY

Benzinga
·
Aug 26, 2025

Press Release: Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

Dow Jones
·
Aug 26, 2025

Molecular Partners AG expected to post a loss of 45 rappen a share - Earnings Preview

Reuters
·
Aug 22, 2025

Molecular Partners Names Martin Steegmaier as Chief Scientific Officer

MT Newswires Live
·
Aug 21, 2025